MedTrace Logo

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

NCT07054099 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 474

Last updated 2026-04-17

No results posted yet for this study

Summary

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

Conditions

  • Varicella (Chickenpox)
  • Chickenpox Vaccine

Interventions

BIOLOGICAL

MG1111 (Barycela inj.)

MG1111 (Barycela inj.)

BIOLOGICAL

VARIVAX™

Varivax™

Sponsors & Collaborators

  • GC Biopharma Corp

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-08-31
Completion
2036-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054099 on ClinicalTrials.gov